Enhanced External Counterpulsation in Patients With Heart Failure: A Multicenter Feasibility Study

Ozlem Soran, MD, Bruce Fleishman, MD, Theresa Demarco, MD, William Grossman, MD, Virginia M. Schneider, RN, Karen Manzo, RN, Paul-André de Lame, MD, Arthur M. Feldman, MD, PhD


CHF. 2002;8(4) 

In This Article


The demographics and characteristics of the study population are shown in Table I . Of the 32 patients enrolled in the study, 21 had an ischemic etiology for their heart failure and 11 had idiopathic cardiomyopathy. The majority of patients were men. Six of the 32 patients were withdrawn before receiving study treatment, five because they met an exclusion criterion during the baseline period and one because of an adverse event that occurred shortly after the initial visit. The remaining 26 patients (19 with ischemic cardiomyopathy and seven with idiopathic cardiomyopathy) received EECP, but three of these patients were discontinued during the treatment period because of adverse events. The remaining 23 patients completed the treatment, including the 1-week follow-up. Of these, 18 completed the whole study per protocol, and one had a minor protocol violation that did not prevent evaluation of efficacy data at the 6-month follow-up. Four patients had protocol violations sufficient to affect efficacy data at the 6-month follow-up. Thus, a total of 19 patients were evaluated for efficacy at the 6-month follow-up.